0.30Open0.30Pre Close0 Volume30 Open Interest8.00Strike Price0.00Turnover268.85%IV107.50%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.2499Delta0.1168Gamma13.33Leverage Ratio-0.0186Theta0.0004Rho3.33Eff Leverage0.0032Vega
Trevi Therapeutics Stock Discussion
📊⚡️📊
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Thursday, 12th December at 7:30 am
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 20...
Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
No comment yet